Skip to main content

Table 4 Final Model of Time until LDL Cholesterol Control

From: A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control

 

Hazard

95% CI

 

Characteristic

Ratio

Lower

Upper

P value

Gender-race

    

Black women

0.66

0.56

0.78

< 0.0001

Black men

0.82

0.69

0.98

0.029

White women

0.75

0.64

0.88

< 0.0001

Baseline LDL cholesterol (quartile)

    

Second

0.89

0.78

1.01

0.082

Third

0.67

0.58

0.77

< 0.0001

Fourth

0.48

0.42

0.56

< 0.0001

Total lipid-lowering drug potency

    

Low

1.23

1.08

1.41

0.001

High

1.85

1.63

2.1

< 0.0001

LDL checks in first 6 months

    

1-2

2.79

2.33

3.35

< 0.0001

3+

4.41

3.58

5.44

< 0.0001

Age [years]

    

61-70

1.1

0.98

1.25

0.114

71-80

1.28

1.11

1.47

0.001

> 80

1

0.84

1.21

0.96

Median neighborhood (per $1000 increase)

1

1

1.01

0.016

Smoking status

    

Current

0.99

0.84

1.18

0.934

Not reported

1.04

0.93

1.17

0.512

Vascular disease

0.8

0.7

0.92

0.001

Unrelated comorbidities (per comorbidity)

1.04

1.02

1.06

< 0.0001

Diabetes

0.81

0.72

0.9

< 0.0001

Chronic renal insufficiency

1.26

1.05

1.52

0.012

Insurance type

    

Medicaid

0.87

0.72

1.04

0.128

Medicare

0.97

0.86

1.1

0.623

Self pay

0.85

0.42

1.71

0.641

High patient adherence to visits

1.31

1.13

1.51

< 0.0001

Antihypertensive drugs (N)

0.98

0.93

1.02

0.299

Provider type

    

Resident

1.15

0.96

1.38

0.117

Other clinician

1.01

0.86

1.19

0.897

Provider race

    

Asian

1.07

0.85

1.33

0.57

Black or other

0.99

0.84

1.16

0.877

Female provider

1.03

0.9

1.18

0.645

Provider workload (quartile of annual visits)

    

Second

1.02

0.88

1.19

0.788

Third

0.96

0.82

1.12

0.58

Fourth

0.94

0.78

1.14

0.535

Patient visits (quartile of annual visits)

    

Second

1.01

0.88

1.16

0.896

Third

1.09

0.95

1.25

0.24

Fourth

1.01

0.87

1.18

0.867